On December 12, 2025, Century Therapeutics, Inc. (IPSC) disclosed positive clinical and preclinical data for three of its induced pluripotent stem cell (iPSC)-derived therapy candidates. The 8-K filing, referencing a corporate presentation, detailed progress for CNTY-101 in autoimmune diseases, CNTY-813 in Type 1 Diabetes, and CNTY-308 in B-cell-mediated diseases.

For its lead candidate, CNTY-101, a therapy for autoimmune diseases including systemic lupus erythematosus (SLE) and lupus nephritis (LN), the company reported Phase 1/2 data showing deep B-cell depletion in blood and lymph nodes. According to the filing, the candidate also demonstrated naive non-class-switched B-cell reconstitution and was detected in lymph node tumor biopsies early post-treatment.

In its diabetes program, CNTY-813 beta islets with Allo-Evasion 5.0 technology restored normoglycemia in streptozotocin-rendered Type 1 Diabetes mouse models, achieving over 99 percent endocrine purity. The company stated that IND-enabling studies for CNTY-813 are expected to begin by the end of 2025, with an Investigational New Drug (IND) submission planned as early as 2026.

The filing also highlighted progress for CNTY-308, an iPSC-derived CAR-T candidate for B-cell-mediated diseases. Preclinical data indicated high functional persistence, cytotoxic effector function, and long-term in vivo persistence comparable to primary CAR-T cells. Century Therapeutics expects CNTY-308 to enter the clinic in 2026.

The corporate presentation referenced in the 8-K outlined planned key clinical milestones for the fourth quarter of 2027. The filing included standard risk factor disclosures, noting uncertainties in clinical development, regulatory timelines, and reliance on collaborative relationships for manufacturing.